يعرض 1,621 - 1,640 نتائج من 13,767 نتيجة بحث عن '(( significantly increased decrease ) OR ( significant ((event decrease) OR (point decrease)) ))', وقت الاستعلام: 0.59s تنقيح النتائج
  1. 1621
  2. 1622
  3. 1623
  4. 1624

    Time Course of the RAAS. حسب Ningning Wang (560944)

    منشور في 2025
    الموضوعات:
  5. 1625
  6. 1626
  7. 1627
  8. 1628

    Flow diagram of patient recruitment. حسب Ningning Wang (560944)

    منشور في 2025
    الموضوعات:
  9. 1629
  10. 1630
  11. 1631
  12. 1632
  13. 1633

    Mechlorethamine gel causes epithelium thinning, epithelium-stroma separation, and decreased total stroma cell count. حسب Ana M. Sandoval-Castellanos (11611315)

    منشور في 2025
    "…<p>A) Epithelium thickness decreased, and B) the percentage of epithelium-stroma separation increased after NM exposure. …"
  14. 1634
  15. 1635

    Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx حسب Qiong Jie (13270095)

    منشور في 2024
    "…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"
  16. 1636

    Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF حسب Qiong Jie (13270095)

    منشور في 2024
    "…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"
  17. 1637

    Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx حسب Qiong Jie (13270095)

    منشور في 2024
    "…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"
  18. 1638

    Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF حسب Qiong Jie (13270095)

    منشور في 2024
    "…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"
  19. 1639
  20. 1640